Short-term Study of Two Soft Contact Lenses in Wearers With Low Astigmatism
Launched by COOPERVISION INTERNATIONAL LIMITED (CVIL) · Mar 7, 2025
Trial Information
Current as of April 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare the performance of two different types of soft contact lenses specifically for people with low astigmatism (a common vision condition where the eye is not perfectly round). The study is open to individuals aged 17 to 42 who wear regular spherical soft contact lenses (not those designed for astigmatism or multifocal lenses). Participants will need to wear the study lenses for about 12 hours a day, six days a week, and answer a few brief online questionnaires during the study period.
To be eligible for this trial, you should be in the specified age range, have low levels of astigmatism, and have worn regular soft contact lenses before. You cannot have any serious eye conditions or have recently worn certain types of contact lenses that could interfere with the study. If you choose to participate, you'll receive clear instructions and your involvement will help researchers learn more about how these lenses perform, which could lead to better options for people with similar vision needs in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. At least 17 years and no more than 42 years of age.
- • 2. Have read and signed the study consent form.
- • 3. Are willing and able to follow instructions and maintain the appointment schedule.
- • 4. Are habitual wearer of spherical soft contact lenses (not toric or multifocal design), any brand and any replacement frequency.
- • 5. Are willing to wear the study contact lenses for 6 days a week while in this study and on three days (day 1, Day 7 and Day 13) for at least 12 hours.
- • 6. Are willing to provide a contact email and telephone number and to use a device that allows them to respond to a short online questionnaire every 3 hours on days 1, 7 and 13 of each lens arm, while wearing one of the 2 study lenses.
- • 7. Are non-presbyopic i.e. no requirement for a reading addition for routine daily tasks (self report).
- • 8. Have astigmatism of either -0.50, -0.75, -1.00 or -1.25 DC in each eye by subjective sphero-cylindrical refraction.
- • 9. Achieves at least 0.10 LogMAR in each eye by subjective sphero-cylindrical refraction.
- • 10. Can be fit with available study contact lens powers of between +6.00 to -10.00 DS.
- • 11. Demonstrate an acceptable fit with the study contact lenses.
- Exclusion Criteria:
- • 1. Are participating in any concurrent clinical interventional study.
- • 2. Have worn rigid contact lenses in the last 3 months.
- • 3. Have worn soft toric contact lenses in the past 3 months.
- • 4. Have any known active ocular disease or allergies and/or infection.
- • 5. Have clinically significant biomicroscopy findings or have an ocular condition that contraindicate contact lens wear.
- • 6. Have a systemic condition that in the opinion of the investigator may affect a study outcome variable or contraindicate wearing soft contact lenses.
- • 7. Are using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable or contraindicate wearing soft contact lenses.
- • 8. Have known sensitivity to the diagnostic sodium fluorescein to be used in the study.
- • 9. Have undergone refractive error surgery or intraocular surgery.
- • 10. Are an employee of the Centre for Ocular Research \& Education directly involved in this study.
Trial Officials
Lyndon Jones, PhD,FCOptom
Principal Investigator
Centre for Ocular Research and Education
About Coopervision International Limited (Cvil)
CooperVision International Limited (CVIL) is a leading global manufacturer of contact lenses and related products, dedicated to enhancing vision health and improving the quality of life for wearers worldwide. With a strong commitment to innovation and research, CVIL invests in clinical trials to develop advanced lens technologies and solutions tailored to diverse vision needs. The company operates with a focus on safety, efficacy, and customer satisfaction, ensuring that their products meet the highest standards of quality and performance. Through partnerships and collaborations, CVIL continues to drive advancements in the eye care industry while prioritizing patient outcomes and satisfaction.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Waterloo, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported